Evidence map›Paper›PMID 27894306›Full record

Trial reportRetrovirology2016

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.

Eunsil Choi, Chad J Michalski, Seung Ho Choo, Gyoung Nyoun Kim, Elizabeth Banasikowska, Sangkyun Lee, Kunyu Wu, Hwa-Yong An, Anthony Mills, Stefan Schneider and 10 more

Open access · goldAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Retrovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Eunsil ChoiDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Chad J MichalskiDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Seung Ho ChooSumagen Canada Inc., London, ON, Canada.
Gyoung Nyoun KimDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Elizabeth BanasikowskaDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Sangkyun LeeSumagen Canada Inc., London, ON, Canada.
Kunyu WuDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Hwa-Yong AnDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Anthony MillsAnthony M. Mills Internal Medicine, West Hollywood, CA, USA.
Stefan SchneiderLong Beach Education and Research Consultants, Long Beach, CA, USA.
U Fritz BredeekMetropolis Medical PC, San Francisco, CA, USA.
Daniel R CoulstonRockwood Clinics, P.C., Spokane, WA, USA.
Shilei DingCentre de Recherche du CHUM, Department of Microbiology, Université de Montréal, Montreal, QC, Canada.
Andrés FinziCentre de Recherche du CHUM, Department of Microbiology, Université de Montréal, Montreal, QC, Canada.
Meijuan TianDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Katja KleinDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Eric J ArtsDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Jamie F S MannDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
Yong GaoDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada.
C Yong KangDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, 1400 Western Road, London, ON, N6G 2V4, Canada. cykang@uwo.ca.
Western University · CACentre Hospitalier de l’Université de Montréal · CARockwood Clinic · USSouthern California Institute for Research and Education · US

Funding

Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
Intersubtype recombinants for polyvalent anti-HIV vaccineR01AI084816 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI GAO, YONG · 2009 to 2013
$3.4M
HIV-1 Fitness and RecombinationR56AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2012 to 2012
$400k
Impact of HIV-1 Fitness on Disease ProgressionR21AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2001 to 2001
$265k
NIAID NIH HHS R01 AI049170NIAID NIH HHS R01 AI084816NIAID NIH HHS R21 AI049170NIAID NIH HHS R56 AI049170
6 · The paper itself

Abstract

backgroundVaccination with inactivated (killed) whole-virus particles has been used to prevent a wide range of viral diseases. However, for an HIV vaccine this approach has been largely negated due to inherent safety concerns, despite the ability of killed whole-virus vaccines to generate a strong, predominantly antibody-mediated immune response in vivo. HIV-1 Clade B NL4-3 was genetically modified by deleting the nef and vpu genes and substituting the coding sequence for the Env signal peptide with that of honeybee melittin signal peptide to produce a less virulent and more replication efficient virus. This genetically modified virus (gmHIV-1

resultsGenetically modified and killed whole-HIV-1 vaccine, SAV001, was well tolerated with no serious adverse events. HIV-1

conclusionThe killed whole-HIV vaccine, SAV001, is safe and triggers anti-HIV immune responses. It remains to be determined through an appropriate trial whether this immune response prevents HIV infection.

Indexed as

AIDS VaccinesImmunogenicity, VaccineAdultAnimalsAntibodies, NeutralizingBeesFemaleGene Products, nefHIV-1HIV AntibodiesHIV InfectionsHuman Immunodeficiency Virus ProteinsHumansMaleMiddle AgedProtein Sorting SignalsAIDS VaccinesAntibodies, NeutralizingGene Products, nefHIV AntibodiesHuman Immunodeficiency Virus ProteinsProtein Sorting SignalsVaccines, InactivatedViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1AIDSClinical trialHIVImmune responsesKilled whole-HIV vaccineNeutralizing antibodiesSafety

Identifiers

PMID27894306
PMCPMC5126836
OpenAlexW2559546630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.